While macro headlines continue to dominate investor attention, small-cap specialty pharma company Collegium Pharmaceutical (NASDAQ: COLL) is quietly executing a disciplined growth strategy — and its latest move is hard to ignore.
The Stoughton, Massachusetts-based company announced a definitive agreement to acquire AZSTARYS, an FDA-approved ADHD treatment, from privately held Corium Therapeutics for $650 million in cash at closing, with the potential for up to $135 million in additional milestone payments tied to future commercial and regulatory targets. The deal is expected to close in the second quarter of 2026.
What Is AZSTARYS and Why Does It Matter?
AZSTARYS is a central nervous system stimulant combining immediate-release and long-acting components in a single capsule, approved for patients aged six and older with Attention Deficit Hyperactivity Disorder. It is one of the more differentiated products in the ADHD space precisely because of that dual-mechanism delivery — something that sets it apart from a crowded field of single-mechanism competitors.
The commercial traction is already there. AZSTARYS generated more than 760,000 prescriptions in 2025, and Collegium projects the drug will contribute over $50 million in pro forma net revenue in just the second half of 2026 — assuming the deal closes on schedule. Six Orange Book-listed patents, most of which do not expire until December 2037, provide long-runway exclusivity that gives this asset real staying power on Collegium’s balance sheet.
Collegium already markets Jornay PM, a delayed-release methylphenidate treatment for ADHD. Adding AZSTARYS gives the company two commercially differentiated products targeting the same condition but with distinct dosing profiles — a smart way to expand market penetration without cannibalizing existing revenue.
The deal structure reflects that discipline. Collegium plans to fund the acquisition using cash on hand and a previously arranged $300 million delayed-draw term loan, with management projecting post-close net leverage of approximately two times estimated 2026 combined adjusted EBITDA. Run-rate cost synergies are expected to exceed $50 million within twelve months of closing, driven by Collegium leveraging its existing ADHD commercial infrastructure rather than building a parallel one from scratch.
The transaction has been unanimously approved by the boards of both companies and is subject to customary regulatory approvals, including Hart-Scott-Rodino clearance.
At a market cap of approximately $1.15 billion, Collegium is doing something many larger companies struggle with — making acquisitions that are both strategically coherent and financially disciplined. The AZSTARYS deal is not a moonshot. It is a calculated bet on a proven, revenue-generating asset with durable patent protection in a therapeutic category — ADHD — that continues to see strong and growing demand across both pediatric and adult patient populations.
Needham & Company reaffirmed its Buy rating on COLL this week with a price target of $56, representing meaningful upside from the stock’s current trading range near $36. The broader analyst consensus sits at Buy, though the stock has traded down from its 52-week high near $51 amid broader market volatility.
For investors focused on the small and microcap space, Collegium’s approach offers a case study in how companies under $2 billion in market cap can use M&A not as a hail mary, but as a precision tool for compounding long-term value.
